https://ipsen-com.agentsite.network/index.html 2026-09-07 daily 0.9 https://ipsen-com.agentsite.network/content/press-release/ipsen-and-exicure-enter-into-exclusive-collaboration-targeting-rare-neurodegenerative-disorders-2.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-to-acquire-albireo-accelerating-growth-in-rare-disease-with-treatments-for-several-pediatric-liver-diseases.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-to-acquire-clementia-pharmaceuticals-to-significantly-boost-rare-disease-portfolio.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/media-resources/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysport-and-botox-in-adults-with-upper-limb-spasticity-3297909.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-completes-acquisition-of-epizyme-expanding-its-portfolio-in-oncology.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-s-a-publishes-its-2026-half-year-report-half-year-ended-30-june-2026-3336267.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/aus/responsibility/governance/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-and-foreseen-biotechnology-announce-exclusive-global-licensing-agreement-for-antibody-drug-conjugate-with-first-in-class-potential-2911523.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-updates-on-qm-1114-regulatory-process/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/dysport-is-the-first-botulinum-toxin-to-achieve-positive-topline-phase-iii-results-in-both-episodic-and-chronic-migraine-3324543.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/investors/financial-results/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-to-acquire-exclusive-rights-to-investigational-erk-inhibitor-as-part-of-its-existing-research-collaboration-with-agv-discovery.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-presents-strong-full-year-2021-results-and-enters-into-exclusive-negotiations-to-divest-its-consumer-healthcare-business.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/stories/sustainability/ipsens-2025-sustainability-statement-is-availab/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/uk-ireland/press-releases/cabozantinib-ipsen-cabozantinib-accepted-by-scottish-medicines-consortium-for-adults-with-advanced-neuroendocrine-tumours.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/careers/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/update/esmo-2025-new-data-reinforces-breadth-and-depth-of-ipsens-growing-oncology-pipeline-and-portfolio-3165272.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-and-genfit-enter-into-exclusive-licensing-agreement-for-elafibranor-a-phase-iii-asset-evaluated-in-primary-biliary-cholangitis-as-part-of-a-long-term-global-partnership.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-and-irlab-enter-exclusive-worldwide-licensing-agreement-aimed-to-improve-the-lives-of-people-living-with-parkinsons-disease.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/investors/reports-and-accounts/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/site-root.html 2026-09-07 monthly 1.0 https://ipsen-com.agentsite.network/content/investors/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-to-acquire-kartos-therapeutics-expanding-hemato-oncology-late-stage-pipeline-3318643.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-and-sutro-biopharma-announce-exclusive-global-licensing-agreement-for-an-adc-targeting-solid-tumors.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-and-blueprint-medicines-announce-exclusive-global-license-agreement-to-develop-and-commercialize-blu-782-for-the-treatment-of-fibrodysplasia-ossificans-progressiva-fop.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/careers/working-at-ipsen/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-and-marengo-therapeutics-announce-strategic-partnership-to-advance-two-precision-immuno-oncology-candidates-from-marengos-star-platform-into-the-clinic.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-expands-early-development-pipeline-with-simcere-zaimings-innovative-antibody-drug-conjugate-3208932.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/us/compliance/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/us/midsize-big-vision/5-ways-ipsen-keeps-compliance-at-our-core/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/investors-suscribe-to-ipsen-news/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/careers/our-culture/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/arbitration-tribunal-upholds-ipsens-termination-of-rd-agreement-with-galderma-3223087.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/germany/product/dysport-abobotulinumtoxina/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/investors/regulated-information/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-to-acquire-memo-therapeutics-ag-adding-first-in-class-bk-polyomavirus-antibody-expanding-rare-disease-portfolio-3320317.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/sustainability/governance/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/sustainability/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-completes-acquisition-of-albireo-expanding-the-scope-of-its-rare-disease-portfolio.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/investors/shareholders-information/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/event/morgan-stanley-healthcare-conference/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-and-day-one-enter-into-exclusive-ex-u-s-licensing-agreement-to-commercialize-tovorafenib-for-the-most-common-childhood-brain-tumor-2918482.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/annual-report/2025-integrated-annual-report/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-delivers-excellent-h1-2026-results-and-upgrades-its-full-year-guidance-3335743.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-adds-another-program-into-its-pre-clinical-rd-oncology-pipeline-through-an-exclusive-worldwide-collaboration-with-accent-therapeutics-targeting-the-rna-modifying-protein-mettl3.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/investors/investor-events/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/media-updates/index.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/press-release/ipsen-to-acquire-epizyme-expanding-its-portfolio-in-oncology.html 2026-09-07 monthly 0.8 https://ipsen-com.agentsite.network/content/newsroom-subscribe-to-ipsen-news/index.html 2026-09-07 monthly 0.8